Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

Published by Global Data on 1st December 2019 | Ref: 1464200 | This Product Is In Stock

$4000 | Single User
$8000 | Site License
$12000 | Enterprise License
$4000 | Single User
$8000 | Site License
$12000 | Enterprise License

Introduction

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

Table of Contents

1.1 List of Tables 10

1.2 List of Figures 16

2 Introduction 17

2.1 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Overview 17

3 Products under Development 18

3.1 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development 18

3.2 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Territory 19

3.3 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Regulatory Path 20

3.4 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Estimated Approval Date 21

3.5 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Ongoing Clinical Trials 22

4 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products under Development by Companies 23

4.1 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Companies - Pipeline Products by Stage of Development 23

4.2 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development 26

5 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Companies and Product Overview 30

5.1 Abreos Biosciences Inc Company Overview 30

5.2 Acetaminophen Toxicity Diagnostics, LLC Company Overview 44

5.3 Affinergy LLC Company Overview 45

5.4 Am Biotechnologies, LLC Company Overview 46

5.5 Analyticon Biotechnologies AG Company Overview 48

5.6 AnaZyme, LLC Company Overview 50

5.7 Angle Biosciences Inc Company Overview 52

5.8 Atonomics A/S Company Overview 53

5.9 Augurix SA Company Overview 54

5.10 Baebies Inc Company Overview 55

5.11 Biocross SL Company Overview 58

5.12 Bioftalmik Applied Research Company Overview 60

5.13 BioMedomics Inc Company Overview 61

5.14 Biotech Resources Pty Ltd Company Overview 63

5.15 Burnet Institute Company Overview 64

5.16 Carclo Diagnostic Solutions Ltd Company Overview 65

5.17 CardioGenics Inc Company Overview 67

5.18 Cellex Inc. Company Overview 70

5.19 Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina Company Overview 71

5.20 Claremont BioSolutions Company Overview 72

5.21 Columbia University Company Overview 73

5.22 CTK Biotech, Inc. Company Overview 75

5.23 DiaSys Diagnostic Systems GmbH Company Overview 76

5.24 Edan Instruments Inc Company Overview 78

5.25 Enesi Pharma Ltd Company Overview 80

5.26 Enigma Diagnostics Ltd (Inactive) Company Overview 81

5.27 Erytech Pharma SA Company Overview 82

5.28 FK-Biotecnologia SA Company Overview 83

5.29 Foundation for Innovative New Diagnostics Company Overview 86

5.30 Gendiag Company Overview 87

5.31 Group K Diagnostics Company Overview 88

5.32 Instrumentation Laboratory Co Company Overview 91

5.33 Integrated Diagnostics Inc (Inactive) Company Overview 92

5.34 IntraMed Diagnostics, LLC Company Overview 93

5.35 IPI Singapore Company Overview 95

5.36 Iron Horse Diagnostics, Inc. Company Overview 96

5.37 Kenyatta University Company Overview 97

5.38 Massachusetts Institute of Technology Company Overview 98

5.39 Medical University of South Carolina Company Overview 100

5.40 Monash University Company Overview 101

5.41 Montana State University Company Overview 102

5.42 NanoSpeed Diagnostics Inc Company Overview 103

5.43 Novartis AG Company Overview 106

5.44 Oasis Diagnostics Corp Company Overview 109

5.45 Ohmx Corp Company Overview 110

5.46 OPKO Health Inc Company Overview 115

5.47 Oxford Immunotec Ltd Company Overview 117

5.48 P2D Inc Company Overview 118

5.49 Philips Healthcare Company Overview 120

5.50 Pop Test LLC Company Overview 121

5.51 PortaScience Inc Company Overview 123

5.52 Quidel Corp Company Overview 124

5.53 SaltCheck Inc (Inactive) Company Overview 126

5.54 Seattle Children's Hospital Company Overview 127

5.55 SenGenix Inc Company Overview 128

5.56 SuperNova Diagnostics, Inc. Company Overview 130

5.57 Systagenix Wound Management Ltd Company Overview 131

5.58 The University of New South Wales press Limited Company Overview 132

5.59 Thermo Fisher Scientific Inc Company Overview 133

5.60 Trivitron Healthcare Pvt Ltd Company Overview 134

5.61 True Diagnostics Inc Company Overview 135

5.62 Universal Biosensors Inc Company Overview 136

5.63 University College Cork Company Overview 137

5.64 University of Edinburgh Company Overview 138

5.65 University of South Australia Company Overview 140

5.66 Wellstat Diagnostics LLC Company Overview 141

6 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Recent Developments 142

6.1 Nov 12, 2019: VolitionRx announces third quarter 2019 financial results and business update 142

6.2 Nov 07, 2019: Celcuity reports third quarter 2019 financial results 143

6.3 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI 145

6.4 Nov 05, 2019: BD announces results for 2019 fourth fiscal quarter and full year; provides fiscal 2020 guidance 146

6.5 Nov 05, 2019: OPKO Health reports 2019 third quarter business highlights and financial results 148

6.6 Oct 31, 2019: Cesca Therapeutics to change name and ticker symbol to reflect new strategic focus 149

6.7 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results 150

6.8 Oct 31, 2019: Surmodics reports fourth quarter fiscal 2019 results and issues fiscal 2020 revenue and EPS Guidance 151

6.9 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results. 152

6.10 Oct 30, 2019: Quidel reports third quarter 2019 financial results 153

7 Appendix 400

7.1 Methodology 400

7.2 About GlobalData 403

7.3 Contact Us 403

7.4 Disclaimer 403

Additional Details

Publisher

Global Data

Publisher Information

Reference

1464200 | GDME0830EPD

Number of Pages

403

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

This report is published by Global Data

Global Data deliver comprehensive, detailed market intelligence that provides a definitive picture of the markets they serve. Their data is complete, detailed, global and completely cross-country comparable.

With different types of data other providers don’t provide, our clients can access a variety of tools that add context to our core data including innovation tracking, sentiment analysis, price monitoring, M&A tracking, competitor intelligence, and city-level intelligence.

Download Free Report Summary PDF

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.